Medtronic, Boston Scientific Corporation, Abbott are dominating the Global Deep Brain Stimulation Systems Market in 2019

Global Deep Brain Stimulation Systems Market is projected to register a substantial CAGR of 8.5% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below:

 Access Full Report at https://www.databridgemarketresearch.com/reports/global-deep-brain-stimulation-systems-market

Global deep brain stimulation systems market is a highly concentrated market which includes key players and local players. The market has witnessed increased various strategic developments owing to favourable market scenario. The market has a prominent growth in upcoming years due to growing demand for the deep brain stimulation systems, booming across healthcare, technological advancements of deep brain stimulation systems introduction of novel automated systems. The market has witness developments in terms of merger and acquisitions, partnerships or product launches to enhance the product portfolio to meet the rising demand of innovative monitoring technology in deep brain stimulation systems. For instance,

 In August 2019, Boston Scientific Corporation received FDA (Food and Drug Administration) approval for their MRI labelling for Vercise Gevia Deep Brain Stimulation System. After receiving approval from FDA, the company will expand the user base as well as its market size.

Medtronic is the dominating player in the global deep brain stimulation systems market. The other key players in the market are Abbott, Boston Scientific Corporation, Aleva Neurotherapeutics SA, SceneRay Corporation, Limited, NeuroPace, Inc., Fisher Wallace and Beijing PINS Medical Co., Ltd. among others.   

Medtronic   

Medtronic is headquartered in Dublin, Ireland and was founded in 1949. The company develops and manufactures a wide range of products and therapies with emphasis on providing a complete training to cardiologists on implantation of devices. Medtronic is a public ownership company. It has more than 90,000 employees. The company has various business segments cardiac & vascular group, minimally invasive therapies group, restorative therapies group, and diabetes group. In this minimally invasive therapies group is the market focused business segment. The company has wide range of product category such as patients & caregivers, healthcare professionals. In this healthcare professionals are market focused categories.

The company is continuously engaged in strategic relationship to enhance the product of the deep brain stimulation systems such as,   

In October 2019, Medtronic announced that they have launched a brain-stim program on a Samsung phone. This program allows the patients to manage their treatments of deep brain stimulation at home with using a Samsung smartphone. By the launching of this advanced program, company expands the product portfolio as well as its user base.

The company has its presence in North America, Europe, Middle East & Africa, Asia-Pacific and South America. The company has subsidiaries such as Covidien (Irish), Corventis,Inc. (U.S.),TyRx Pharma Inc. (U.S.), ATS Medical (U.S.),Given Imaging (Israel), United States Surgical Corporation (U.S.) among others.  

BOSTON SCIENTIFIC CORPORATION

Boston Scientific Corporation is headquartered in Massachusetts, U.S and was founded in 1979. The main focus of the company is to provide medical solutions for their patients across the world. Boston Scientific Corporation is a public ownership company. The company has 32,000 employees in the company. The company has various business segments cardiovascular, rhythm management, medsurg. In this MedSurg is the market focused business segment. The company has wide range of product category such as Access Device: Dilatation, Access Device: Sheath, Accessories, Antiretropulsion, Artificial Urinary Sphincter, Atherectomy Systems, Balloons: Cutting, Balloons: Dilation and Extraction, Band Ligator, Baskets, Bronchial Thermoplasty, Capital Equipment: Diagnostic, Capital Equipment: Mapping & Navigation, Capital Equipment: Therapy, Catheters: Ablation, Catheters: Balloon, Catheters: Diagnostic, Catheters: Drainage, Catheters: Guide, Catheters: Mapping, Catheters: Ureteral, Clips, Stents Coronary, CRT-D, CRT-P, CTO Systems, Cytology Brushes, Deep Brain Stimulation Systems, Defibrillators (ICD), Direct Visualization Systems, Embolic Protection, Embolization, Endoluminal Surgery Devices, Endometrial Ablation System, Enteral Access & Feeding Tubes, Exchange Device, FFR & IVUS Systems, Fiducial Markers, Forceps, Guidewires, Infection Prevention, Introducer Sheaths, Laser Fibers & Accessories, Lasers, BPH & Lithotripsy, Leads, Left Atrial Appendage Closure Device, Lifting Agents, Microcatheters, Needles, Pacemakers, PCNL, Pelvic Floor Reconstruction, Penile Prosthesis, Plaque Modification, Probes, Radiofrequency Ablation for Pain Management, Remote Patient Monitoring and Diagnostic Monitoring, Retrieval Devices, RF Ablation, Slings: Mid-Urethral and others. In this deep brain stimulation systems are market focused categories.   

The company is continuously engaged in strategic relationship to enhance the product of the deep brain stimulation systems such as,    

  • In January 2019, Boston Scientific Corporation announced that they have launched Vercise Primary Cell (PC) and Vercise Gevia Deep Brain Stimulation Systems featuring Vercise Cartesia directional lead. This new product is used in the treatment of Parkinson's disease. By launching the new product company expand their product portfolio. 

The company has its presence in the U.S, Asia-Pacific, Europe, Latin America and South Africa. The company has subsidiaries such as Guidant Global (U.K.), Augmenix, Inc. (U.K.), American Medical Systems, LLC (U.S.), Symetis SA (Switzerland), Claret Medical (U.S.) among others.

Abbott   

Abbott is headquartered in Illinois, U.S. and was founded in 1888. The company is focusing on products and services for cardio metabolic disease, infectious disease and toxicology. Abbott is a public ownership company. Company has more than 103,000 employees in the company. The company has various business segments established pharmaceuticals, nutritionals, diagnostic, cardiovascular and neuromodulation. In this cardiovascular and neuromodulation is the market focused business segment. The company has wide range of product category such as cardiovascular, diabetes care, diagnostics, neuromodulation, nutrition, medicines. In this neuromodulation are market focused categories.    

  • In January 2019, Abbott announced that they have received CE mark approval for their Bluetooth-enabled software upgrades to all currently installed Infinity DBS systems which deliver MR-conditional labelling and innovative features. After receiving CE mark approval, the company commercialize and expand their business in the market

The company has presence in Europe, Asia-Pacific, Middle East & Africa, North America and South America. The company has various subsidiaries such as La Abbott Administration Inc (Delaware), Abbott Cardiovascular Systems Inc. (California), Abbott Home Infusion Services of New York, Inc.(New York), Abbott Laboratories (Puerto Rico) Incorporated, EAS Australia Pty Ltd (Australia), Abbott (Cambodia) LLC, Abbott Laboratories A/S (Denmark) among others.

Recent Strategic Decisions

Deep Brain Stimulation Systems Market